Regulatory T cells move in when gliomas say "I Do"

doi:10.1158/1078-0432.CCR-12-2801

Comment

. 2012 Nov 15;18(22):6086-8.

doi: 10.1158/1078-0432.CCR-12-2801. Epub 2012 Oct 10.

Regulatory T cells move in when gliomas say "I Do"

Bryan D Choi¹, Peter E Fecci, John H Sampson

Affiliations

Affiliation

¹ Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

PMID: 23052252
PMCID: PMC3662964
DOI: 10.1158/1078-0432.CCR-12-2801

Comment

Regulatory T cells move in when gliomas say "I Do"

Bryan D Choi et al. Clin Cancer Res. 2012.

. 2012 Nov 15;18(22):6086-8.

doi: 10.1158/1078-0432.CCR-12-2801. Epub 2012 Oct 10.

Authors

Bryan D Choi¹, Peter E Fecci, John H Sampson

Affiliation

¹ Duke Brain Tumor Immunotherapy Program, Preston Robert Tisch Brain Tumor Center, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.

PMID: 23052252
PMCID: PMC3662964
DOI: 10.1158/1078-0432.CCR-12-2801

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an enzyme with known immunosuppressive and tolerogenic effects in cancer. Mounting evidence has associated IDO expression with the induction of regulatory T cells (Treg) and malignant progression. IDO inhibition may therefore provide a promising therapeutic approach for glioblastoma, where the need for novel treatment is great.

PubMed Disclaimer

Conflict of interest statement

The authors do not report conflicts of interest.

Figures

**Figure 1**
T_regs accumulate in brain tumors and are associated with poor prognosis. Peripheral depletion with anti-CD25 antibodies and CTLA-4 blockade are methods by which antitumor immune responses may be enhanced. IDO-mediated catabolism of tryptophan occurs in both tumor cells and peripherally in DCs. Here, IDO enzymatic activity potentiates an immune tolerogenic environment resulting in the reciprocal induction of T_regs amidst a suppressed effector T-cell response.

See this image and copyright information in PMC

Comment on

IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.
Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, Tobias AL, Han Y, Lesniak MS. Wainwright DA, et al. Clin Cancer Res. 2012 Nov 15;18(22):6110-21. doi: 10.1158/1078-0432.CCR-12-2130. Epub 2012 Aug 29. Clin Cancer Res. 2012. PMID: 22932670 Free PMC article.

Cited by

Immunotherapy Resistance in Glioblastoma.
Wang EJ, Chen JS, Jain S, Morshed RA, Haddad AF, Gill S, Beniwal AS, Aghi MK. Wang EJ, et al. Front Genet. 2021 Dec 17;12:750675. doi: 10.3389/fgene.2021.750675. eCollection 2021. Front Genet. 2021. PMID: 34976006 Free PMC article. Review.
A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.
Chung DS, Shin HJ, Hong YK. Chung DS, et al. J Immunol Res. 2014;2014:326545. doi: 10.1155/2014/326545. Epub 2014 Jun 9. J Immunol Res. 2014. PMID: 25009822 Free PMC article. Review.
Immune phenotypes predict survival in patients with glioblastoma multiforme.
Mostafa H, Pala A, Högel J, Hlavac M, Dietrich E, Westhoff MA, Nonnenmacher L, Burster T, Georgieff M, Wirtz CR, Schneider EM. Mostafa H, et al. J Hematol Oncol. 2016 Sep 1;9(1):77. doi: 10.1186/s13045-016-0272-3. J Hematol Oncol. 2016. PMID: 27585656 Free PMC article.
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Brown NF, Ng SM, Brooks C, Coutts T, Holmes J, Roberts C, Elhussein L, Hoskin P, Maughan T, Blagden S, Mulholland P. Brown NF, et al. BMC Cancer. 2020 Mar 12;20(1):198. doi: 10.1186/s12885-020-6624-y. BMC Cancer. 2020. PMID: 32164579 Free PMC article. Clinical Trial.
T-cell Dysfunction in Glioblastoma: Applying a New Framework.
Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. Woroniecka KI, et al. Clin Cancer Res. 2018 Aug 15;24(16):3792-3802. doi: 10.1158/1078-0432.CCR-18-0047. Epub 2018 Mar 28. Clin Cancer Res. 2018. PMID: 29593027 Free PMC article. Review.

See all "Cited by" articles

References

1. Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012 - PMC - PubMed
1. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008;222:70–100. - PMC - PubMed
1. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294–302. - PubMed
1. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8:234–43. - PMC - PubMed
1. Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A, et al. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol. 2009;39:1323–33. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012 - PMC - PubMed

[2] Wainwright DA, Balyasnikova IV, Chang AL, Ahmed AU, Moon KS, Auffinger B, et al. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res. 2012 - PMC - PubMed

[3] Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008;222:70–100. - PMC - PubMed

[4] Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008;222:70–100. - PMC - PubMed

[5] Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294–302. - PubMed

[6] Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294–302. - PubMed

[7] El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8:234–43. - PMC - PubMed

[8] El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8:234–43. - PMC - PubMed

[9] Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A, et al. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol. 2009;39:1323–33. - PubMed

[10] Biollaz G, Bernasconi L, Cretton C, Puntener U, Frei K, Fontana A, et al. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg. Eur J Immunol. 2009;39:1323–33. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Regulatory T cells move in when gliomas say "I Do"

Affiliation

Regulatory T cells move in when gliomas say "I Do"

Authors

Affiliation

Abstract

Conflict of interest statement

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials